(r)HDL in theranostics: how do we apply HDL's biology for precision medicine in atherosclerosis management?

Kepa B. Uribe; Asier Benito-Vicente; Cesar Martin; Francisco Blanco-Vaca; Noemi Rotllan

首页> 外文期刊>Biomaterials Science >(r)HDL in theranostics: how do we apply HDL's biology for precision medicine in atherosclerosis management?

【24h】

(r)HDL in theranostics: how do we apply HDL's biology for precision medicine in atherosclerosis management?

机译：（r）HDL在Theranostics：我们如何在动脉粥样硬化管理中申请HDL生物学治疗精密药物？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

High-density lipoproteins (HDL) are key players in cholesterol metabolism homeostasis since they are responsible for transporting excess cholesterol from peripheral tissues to the liver. Imbalance in this process, due to either excessive accumulation or impaired clearance, results in net cholesterol accumulation and increases the risk of cardiovascular disease (CVD). Therefore, significant effort has been focused on the development of therapeutic tools capable of either directly or indirectly enhancing HDL-guided reverse cholesterol transport (RCT). More recently, in light of the emergence of precision nanomedicine, there has been renewed research interest in attempting to take advantage of the development of advanced recombinant HDL (rHDL) for both therapeutic and diagnostic purposes. In this review, we provide an update on the different approaches that have been developed using rHDL, focusing on the rHDL production methodology and rHDL applications in theranostics. We also compile a series of examples highlighting potential future perspectives in the field.

机译：高密度脂蛋白（HDL）是胆固醇代谢稳态的关键球员，因为它们负责将过量的胆固醇从外周组织转移到肝脏。由于过度过度的积累或损害而受损，导致净胆固醇积累并增加心血管疾病（CVD）的风险。因此，重大努力集中在能够直接或间接增强HDL引导的反向胆固醇转运（RCT）的治疗工具的发展。最近，鉴于精密纳米医生的出现，已经需要重新研究兴趣试图利用治疗和诊断目的的先进重组HDL（RHDL）。在本综述中，我们提供了使用RHDL开发的不同方法的更新，专注于TherAnostics中的RHDL生产方法和RHDL应用。我们还编制了一系列示例，突出了该领域的潜在未来观点。

著录项

来源
《Biomaterials Science》 |2021年第9期|共24页
作者
Kepa B. Uribe; Asier Benito-Vicente; Cesar Martin; Francisco Blanco-Vaca; Noemi Rotllan;
展开▼
作者单位

Center for Cooperative Research in Biomaterials (CIC biomaGUNE) Basque Research and Technology Alliance (BRTA) Paseo de Miramon 182 20014 Donostia San Sebastian Spain;

Instituto Biofisika (UPV/EHU CSIC) and Departamento de Bioquimica Universidad del Pais Vasco Apdo.644 48080 Bilbao Spain;

Instituto Biofisika (UPV/EHU CSIC) and Departamento de Bioquimica Universidad del Pais Vasco Apdo.644 48080 Bilbao Spain;

Servei de Bioquimica Hospital Santa Creu i Sant Pau-Institut d'Investigacions Biomediques (IIB) Sant Pau 08041 Barcelona Spain;

Institut de Recerca de l'Hospital Santa Creu i Sant Pau-Institut d'Investigacions Biomediques (IIB) Sant Pau 08025 Barcelona Spain;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类计量学;
关键词

相似文献

外文文献
中文文献
专利

1. Serum TC/HDL-C,TG/HDL-C and LDL-C/HDL-C in predicting the risk of myocardial infarction in normolipidae-mic patients in South Asia:A case-control study [J] . Arun Kumar, Ramiah Sivakanesan 亚太热带医药杂志（英文版） . 2008,第002期
2. A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and development. [J] . Zhao L, Jin W, Rader D Biochemical Pharmacology . 2009,第4期

机译：转化医学对Torcetrapib发育的观点：Torcetrapib发育的失败是否为脂质修饰剂，HDL升高策略或CETP作为动脉粥样硬化的可行分子靶标的未来发展蒙上阴影？在动脉粥样硬化药物发现和开发中使用生物标志物和转化医学的案例研究。
3. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. [J] . Villines TC, Stanek EJ, Devine PJ, Journal of the American College of Cardiology . 2010,第24期

机译：ARBITER 6-HALTS试验（研究动脉粥样硬化减少胆固醇6-HDL和LDL治疗策略的治疗作用的动脉生物学）：最终结果以及药物依从性，剂量和治疗持续时间的影响。
4. Design and Rationale of the ARBITER 6 Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)-6-HDL and LDL Treatment Strategies in Atherosclerosis (HALTS) [J] . Patrick J. Devine, Mark A. Turco, Allen J. Taylor Cardiovascular Drugs and Therapy . 2007,第3期

机译：动脉粥样硬化（HALTS）-6-HDL和LDL治疗策略的ARBITER 6试验（研究降低胆固醇的治疗作用的动脉生物学）的设计和原理
5. Multivalent Peptide-Mimetics of Apolipoprotein A-I That Modulate HDL Particles to Combat Atherosclerosis [C] . Yannan Zhao, Tomohiro Imura, Luke J. Leman American Peptide Symposium . 2013

机译：载脂蛋白A-1的多价肽模拟物，其调节HDL颗粒以对抗动脉粥样硬化
6. Genetic and environmental predictors of HDL cholesterol and atherosclerosis in the NHLBI Family Heart Study (FHS) and the Atherosclerosis Risk in Communities (ARIC) study [D] . Peacock, James Matthew 2002

机译：NHLBI家庭心脏研究（FHS）和社区动脉粥样硬化风险（ARIC）研究中HDL胆固醇和动脉粥样硬化的遗传和环境预测因子
7. Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis [O] . Eftaxia-Konstantina Valanti, Katerina Dalakoura-Karagkouni, Despina Sanoudou 2018

机译：当前和新兴的重组HDL-apoA-I和HDL-apoE治疗动脉粥样硬化的方法
8. (r)HDL in theranostics: how do we apply HDL's biology for precision medicine in atherosclerosis management? [O] . Kepa B. Uribe, Asier Benito-Vicente, Cesar Martin, 2021

机译：（r）HDL在Theranostics中：我们如何在动脉粥样硬化管理中应用HDL生物学以进行精密药物？
9. MOLECULAR DYNAMICS SIMULATION AND EXPERIMENTAL STUDIES OF GOLD NANOPARTICLE TEMPLATED HDL-LIKE NANOPARTICLES FOR CHOLESTEROL (POSTPRINT). [R] . Lai, C., Sun, W., Palekar, R. U., 2016

机译：金属纳米粒子模拟HDL样纳米粒子的胆甾醇（pOsTpRINT）分子动力学模拟及实验研究。

(r)HDL in theranostics: how do we apply HDL's biology for precision medicine in atherosclerosis management?

摘要

著录项

相似文献

相关主题

期刊订阅